Business DevelopmentThe company’s strategy is focused on:
Development of specialty oncology products to be marketed by the Company sales force in Europe and USA, and by partners elsewhere
Development of oncology product candidates with broad cancer applications to be marketed by partners
TopoTarget has built a promising product pipeline by a combination of:
In-house research
Strategic acquisition
Product development partnerships
TopoTarget has a track record of succesfully managing alliances with major pharmaceutical companies, biotechnology companies and academic institutions. The Company will continue this strategy in order to develop a portfolio of oncology product candidates balanced between speciality drugs and products with broader commercial potential. Partnering StrategyIn-Licensing The Company will seek to in-licens pre-clinical and clinical product candidates that match the Company's business goals and strategy to completement the current portfolio:Out-LicensingTopoTarget will capitalize on its skills in drug discovery and clinical development to progres drug candidates into clinical development. For products with major market potential, TopoTarget will seek partnerships with larger pharmaceutical companies to complete clinical development, regulatory approval and product marketing.Overview of Business Development programmes
This text is replaced by the Flash movie.
Current OpportunitiesOut-Licensing
Clinical development and commercialisation partner for belinostat in Europe and Asia (market launch anticipated in 2011)
Development partners in non-oncology indications for our extensive chemical library of HDACi
For more information on the above opportunities please contact: Steven Butcher Chief Operating Officer
Development partners with formulation expertise for the VPA products, Avugane® (acne), and Baceca® (basal cell carcinoma). Phase II clinical data are available for both products
About Us
Cancer
